A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN

Journal of the Neurological Sciences

Volumn 223, Issue 1, 2004, Pages 69-71

  Patti, F ^a   Amato, M P ^b   Filippi, M ^c   Gallo, P ^d   Trojano, M ^e   Comi, G C ^c  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

^e UNIVERSITY OF BARI   (Italy)

Author keywords

Active disease; Combination therapy; Cyclophosphamide

Indexed keywords

BETA INTERFERON; CYCLOPHOSPHAMIDE; NEUTRALIZING ANTIBODY;

ARTICLE; BRAIN ATROPHY; CLINICAL PROTOCOL; CLINICAL TRIAL; COGNITIVE DEFECT; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG SAFETY; EVALUATION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; PERIODIC MEDICAL EXAMINATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SAMPLE SIZE; SIDE EFFECT;

CENTRAL NERVOUS SYSTEM; CLINICAL PROTOCOLS; CYCLOPHOSPHAMIDE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; ITALY; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; RECURRENCE; TREATMENT OUTCOME;

EID: 3142559648     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2004.04.023     Document Type: Article

References (12)

1. Calabresi, PA. Consideration in the treatment of relapsing-remitting multiple sclerosis. Neurology Apr 23;58(8 Suppl 4):S10-22 [Review]
2. Gonsette R.E., Demonty L., Delmotte P. Intensive immunosuppression with cyclophosphamide in multiple sclerosis. Follow-up of 110 patients for 2-6 years. J. Neurol. 214(3):1977;173-181
3. Hommes O.R., Prick J.J., Lamers K.J. Treatment of the chronic progressive form of multiple sclerosis with a combination of cyclophosphamide and prednisone. Clin. Neurol. Neurosurg. 78(1):1975;59-72
4. Hauser S.L., Dawson D.M., Lehrich J.R., et al. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N. Engl. J. Med. 308(4):1983;173-180
5. Likosky W.H., Kaiser Permanent Medical Care Program Experience with cyclophosphamide in multiple sclerosis: the cons. Neurology. 38(Suppl 2):1988;14-18
6. Carter J.L., Hafler D.A., Dawson D.M, et al. Immunosuppression with high-dose i.v. cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients. Neurology. 38(Supp 2):1988;9-14
7. Weiner H.L., Mackin G.A., Orav E.J., et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology. 43(5):1993;910-918
8. The Canadian Cooperative Multiple Sclerosis Study Group The Canadian cooperative trial of cyclophosphamide and plasma-exchange in progressive multiple sclerosis. Lancet. 337:1991;441-446
9. Gobbini M.I., Smith M.E., Richert N.D., et al. Effect on open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis. J. Neuroimmunol. 99:1999;142-149
10. Patti F., Cataldi M.L., Nicoletti F., et al. Combination of cyclophosphamide and interferon beta halts progression in patients with rapidly transitional multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 71:2001;404-407
11. Perini P., Marangoni S., Tzinteva E., et al. Two years therapy of secondary progressive multiple sclerosis (SPMS) with pulse intravenous cyclophosphamide/methylprednisolone. Clinical and MRI data. Mult. Scler. 7:2001;S62
12. Weiner H.L., Cohen J.A. Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Mult. Scler. 8(2):2002;142-154